TopoTarget takes out two patents on drug candidates for cancer treatment  

2005.05.30
Danish biopharmaceutical company TopoTarget has taken out two patents on drug candidates for cancer treatment in the US and Europe respectively

Danish biopharmaceutical company TopoTarget has taken out two patents on drug candidates for cancer treatment in the US and Europe respectively. The US patent covers PXD 101, a HDAC [Histone Deacetylase - Ed] inhibitor currently under development in collaboration with CuraGen Corporation, while the European patent covers Baceca, a product for the treatment of skin cancer, and Peac for the treatment of colon cancer.

Peter Buhl Jensen, director of TopoTarget says the patents are valid until 2021, and that the company expects to have one or more of the products ready for market launch in three to four years. Before that, TopoTarget plans to market its lead product Savene in the US and Europe in 2006. Savene reportedly reduces the damage caused by chemotherapy to healthy tissue, thereby enabling more powerful chemotherapy treatment of cancer cells. The drug is currently in Phase II/III trials.

TopoTarget was formed in 2000 and has grown both organically and through acquisitions. In 2002, the company acquired the UK cell cycle company Profilix, and in 2005 the German company G2M Cancer Drugs. TopoTarget is headquartered in Copenhagen and has subsidiaries in Oxford, UK, and Frankfurt, Germany. The news is reported by national daily newspaper Jyllands-Posten and on TopoTarget's website.

Link > TopoTarget 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×